Study Supports FutureCeuticals Ingredient for Osteoarthritis Relief

The ingredient is a borate complex, containing calcium, boron from plants, and fructose from fruits, nuts, and legumes.

FutureCeuticals Inc. (Momence, IL) has announced the results of a recent clinical pilot study on its patented ingredient FruiteX-B and knee osteoarthritis. The ingredient is a borate complex, containing calcium, boron from plants, and fructose from fruits, nuts, and legumes.

Subjects with knee osteoarthritis were assigned to consume FruiteX-B or placebo for 14 days as researchers assessed daily pain scores using the WOMAC and McGill Pain Questionnaire methods.

By day 7, subjects in the FruiteX-B group demonstrated improvements in pain, stiffness, and physical function, according to WOMAC and McGill scores. By day 14, WOMAC and McGill scores improved by 29% and 14%, respectively.

“Perhaps the best testament to the product’s appeal, subjects in the FruiteX-B group unanimously requested additional product at the conclusion of the study,” said FutureCeuticals vice president of sales Hartley Pond.

The study is now available at the American Journal of Biomedical Sciences.